Conducting CRISPR/dCas9 screens to identify drug resistance mechanisms in neuroblastoma
To wait for resistance to drugs to develop in patients and then identify why it happened, will lead to a deadly lag in the design of salvage therapies or indeed preventative treatment approaches.